Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Acticor Biotech logo — To treat the acute phase of ischemic stroke !

Acticor Biotech

To treat the acute phase of ischemic stroke !

Founded 2013 France France 18 employees Post-IPO Equity Total: $49.30M Biopharma, Biotechnology +2

General Information

Company Name Acticor Biotech
Founded Year 2013
Location France France
Employees 18
Industries Biopharma, Biotechnology, Health and Wellness +1
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Acticor Biotech. To contact Acticor Biotech, visit acticor-biotech.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Acticor Biotech compare?

A PDF of Acticor Biotech and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Acticor Biotech soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Acticor Biotech

Acticor Biotech, a spin-off from Inserm (French National Institute of Health and Medical Research), is focused on developing an innovative therapeutic strategy for the acute phase of ischemic strokes, which constitute 80% of all strokes. The company's project addresses the pressing need for new therapeutic options to manage stroke, considering that 15 million people worldwide suffer from stroke each year, resulting in 5 million deaths and 5 million permanent disabilities. Stroke ranks as the third leading cause of death globally and the primary cause among women, while 75% of survivors sustain neurological damage leading to acquired disabilities. Currently, only one treatment is recommended by health authorities, reaching merely 15% of ischemic stroke patients with less than 40% efficacy. This underscores a substantial need for a new and more effective treatment. Acticor Biotech's project relies on the academic research from its founders, Dr. M. Jandrot-Perrus and Prof. P. Billiald, and has garnered support from prestigious institutions such as the ANR (The French National Research Agency) and the Fondation de France. The project has also been recognized with the 2012 national prize for innovation in creation & development category from the BPI (French Public Investment Bank, formerly OSEO). Founded in 2013 and headquartered in France, Acticor Biotech recently secured an €8.00M Post-IPO Equity investment on 15 March 2024, with investment from UI Investissement, Mediolanum Farmaceutici S.p.A., Gilles Avenard, and Alain Munoz. The company operates in the Biopharma, Biotechnology, Health and Wellness, and Pharmaceutical industries, positioning itself at the forefront of innovative medical advancements to address critical unmet healthcare needs related to ischemic stroke.

Business keywords: biopharmaceuticals, stroke treatment, thrombosis therapy, acute phase drug, monoclonal antibody, drug development, innovative therapy, neurological disorders, biotechnology research, medical research, biomedical science, pharmaceutical innovation

Services & Products

Drug development for thrombotic diseases

Target Customers

Patients suffering from acute ischemic stroke and cardiovascular emergencies

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity €8.00M 4
UI Investissement
UI Investissement, Mediolanum Farmaceutici S.p.A. +2
15 Mar 2024
Post IPO Equity €12.20M 1
Mediolanum Farmaceutici S.p.A.
09 Mar 2023
Series B €7.00M 7
Karista Newton BioCapital Mirae Asset
Karista, Newton BioCapital +5
06 Nov 2019
Series B €15.30M 4
Karista Newton BioCapital Mirae Asset Capital
Karista, Newton BioCapital +2
17 Oct 2018
Series A €1.70M 3
Karista Anaxago Primer Capital
Karista, Anaxago +1
04 Jan 2018
Grant €2.20M 3
Karista Anaxago Primer Capital
Karista, Anaxago +1
04 Jan 2018
Venture Round €1.50M 1
Karista
Karista
07 Feb 2017
Venture Round €1.40M 2
Anaxago
Anaxago, ARMESA
11 Jul 2016
Venture Round Undisclosed 1
AGORANOV
AGORANOV
01 Oct 2010

Acticor Biotech Alternatives & Competitors

View All Alternatives
Acticor Biotech vs
PrecisemAb Biotech Co., Ltd.
PrecisemAb Biotech Co., Ltd. Taiwan

We are committed to changing the world to be better by creating safer and disease-directed Lock-anti...

6 employees
Biotechnology, Health Care
Acticor Biotech vs
Zhimeng Biopharma
Zhimeng Biopharma

Actively advancing innovative small molecule treatments for neurological conditions like epilepsy, p...

Series B
7 employees
Biopharma, Biotechnology
Acticor Biotech vs
NeuroTrauma Sciences, LLC
NeuroTrauma Sciences, LLC

NeuroTrauma Sciences (NTS) is a biopharmaceutical company focused on developing therapies to treat t...

Seed
16 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About Acticor Biotech

To treat the acute phase of ischemic stroke !
Acticor Biotech was founded in 2013.
Acticor Biotech is headquartered in France.
Acticor Biotech operates in Biopharma, Biotechnology, Health and Wellness and Pharmaceutical. Its work centres on biopharmaceuticals, stroke treatment, thrombosis therapy and acute phase drug. Its customers include Patients suffering from acute ischemic stroke and cardiovascular emergencies.
Acticor Biotech has approximately 18 employees.
Acticor Biotech has completed 9 funding rounds, raising a total of $49.30M. The latest funding stage is Post-IPO Equity.
Acticor Biotech offers: Drug development for thrombotic diseases.
Top alternatives and competitors to Acticor Biotech include PrecisemAb Biotech Co., Ltd., Zhimeng Biopharma, NeuroTrauma Sciences, LLC, RogCon, Inc., ImmunGene. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Acticor Biotech and PrecisemAb Biotech Co., Ltd. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Acticor Biotech, https://bouncewatch.com/company/acticor-biotech, updated 11 June 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes